Browsing by Publisher "ELSEVIER ESPANA SLU"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Does atopy affect the course of viral pneumonia?
    (ELSEVIER ESPANA SLU) Erdem, SB; Can, D; Girit, S; Çatal, F; Sen, V; Pekcan, S; Yüksel, H; Bingöl, A; Bostanci, I; Erge, D; Ersu, R
    Background: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised with viral pneumonia. Methods: Children between the ages of 1 and 6 years hospitalised due to viral pneumonia between the years of 2013 and 2016 were included to this multicentre study. Patients were classified into two groups as mild-moderate and severe according to the course of pneumonia. Presence of atopy was evaluated with skin prick tests. Groups were compared to evaluate the risk factors associated with severe viral pneumonia. Results: A total of 280 patients from nine centres were included in the study. Of these patients, 163 (58.2%) were male. Respiratory syncytial virus (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%) were isolated from respiratory samples. Eighty-five (30.4%) children had severe pneumonia. Atopic sensitisation was found in 21.4% of the patients. Ever wheezing (RR: 1.6, 95% CI: 1.1-2.4), parental asthma (RR: 1.5, 95% CI: 1.1-2.2), other allergic diseases in the family (RR: 1.8, 95% CI: 1.2-2.9) and environmental tobacco smoke (RR: 1.6, 95% CI: 1.1-3.5) were more common in the severe pneumonia group. Conclusions: When patients with mild-moderate pneumonia were compared to patients with severe pneumonia, frequency of atopy was not different between the two groups. However, parental asthma, ever wheezing and environmental tobacco smoke exposure are risk factors for severe viral pneumonia in children. (C) 2017 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.
  • No Thumbnail Available
    Item
    Similar prevalence, different spectrum: IgE-mediated food allergy among Turkish adolescents
    (ELSEVIER ESPANA SLU) Mustafayev, R; Civelek, E; Orhan, F; Yüksel, H; Boz, AB; Sekerel, BE
    Background: Scarcity of reliable data on food allergy prevalence exists in Turkey. We aimed to assess reported and confirmed IgE-mediated food allergy prevalence, and define the spectrum of allergenic food. Methods: We prospectively evaluated the ISAAC Phase II study population for food allergy. Participants that reported experiencing food allergy symptom in the last year and/or were skin prick test positive for a predefined list of food allergens, were interviewed via telephone, and those considered as having food allergy were invited to undergo clinical investigation, including challenge tests. Results: A total of 6963 questionnaires were available. Parental reported food allergy prevalence and skin prick sensitisation rate were 20.2 +/- 0.9% and 5.9 +/- 0.6%. According to the above-defined criteria, 1162 children (symptom positive n=909, skin prick test positive n=301, both positive n=48) were selected and 813 (70.0%) were interviewed via telephone. Out of 152 adolescents reporting a current complaint, 87 accepted clinical investigation. There were 12 food allergies diagnosed in nine adolescents, with food allergy prevalence of 0.16 +/- 0.11%. The most common foods involved in allergic reactions were walnut (n=3) and beef meat (n=2), followed by hen's egg (n=1), peanut (n=1), spinach (n=1), kiwi (n=1), cheese (n=1), hazelnut (n=1) and peach (n=1). Conclusions: While parental reported food allergy prevalence was within the range reported previously, confirmed IgE-mediated food allergy prevalence among adolescents was at least 0.16%, and the spectrum of foods involved in allergy differed from Western countries, implying environmental factors may play a role. (C) 2012 SEICAP. Published by Elsevier Espana, S.L. All rights reserved.
  • No Thumbnail Available
    Item
    Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes
    (ELSEVIER ESPANA SLU) Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. (C) 2022 . by the American Thoracic Society, which grants unconditional and unlimited licenses to the European Respiratory Journal, Respirology, Archivos de Bronconeumologia, and Journal of Allergy and Clinical Immunology: In Practice.
  • No Thumbnail Available
    Item
    Assessment of sexual function in women with macromastia and their partners
    (ELSEVIER ESPANA SLU) Üçer, O; Sir, E; Güngör, M; Keçeci, Y; Aksoy, A; Gümüs, B
    Objective: To investigate the sexual function in patients with macromastia and their partners. Materials and methods: 48 patients with macromastia and 30 healthy controls and their partners were enrolled in the study. The sexual function of the women and their partners was evaluated by using the Index of Female Sexual Function (IFSF) and International Index of Erectile Function (IIEF), respectively. Results: Mean ages of the patients and controls were respectively, 33.27 +/- 5.24 and 32.06 +/- 3.91 (p > 0.05). Mean IFSF scores of the patients and controls were 23.21 +/- 3.16 and 27.33 +/- 4.94 (p = 0.00), respectively. All of the subscale scores of IFSF in the patient group were significantly lower than in the control group. Mean IIEF scores of the patients' and controls' partners were 60.33 +/- 11.46 and 65.25 +/- 6.18 (p = 0.04), respectively. Conclusion: In this study, Macromastia was shown to affect sexual function of women and their partners adversely. (C) 2014 Asociacion Espanola de Andrologia, Medicina Sexual y Reproductiva. Published by Elsevier Espana, S.L.U. All rights reserved.
  • No Thumbnail Available
    Item
    Drug allergy in tertiary care in Turkey: Results of a national survey. The ADAPT study: Adult drug allergy perception in Turkey
    (ELSEVIER ESPANA SLU) Çelik, GE; Karakaya, G; Öztürk, AB; Gelincik, A; Abadoglu, Ö; Sin, A; Damadoglu, E; Yilmaz, I; Demirtürk, M; Dursun, B; Özdemir, SK; Çelikel, S; Degirmenci, P; Bozkurt, B; Göksel, Ö; Erkekol, FÖ; Aydin, Ö; Kavut, AB; Kirmaz, C; Kalpaklioglu, F; Büyüköztürk, S; Kalyoncu, F
    Background: No data are available on the incidence of drug hypersensitivity (DH) reactions in outpatient settings of tertiary allergy/immunology clinics. Our aims were to document the frequency of outpatient hospital admissions due to DH reactions to allergy/immunology clinics in adults and the management of these reactions in real life. We also investigated whether drug allergy affected social and medical behaviours of the patients. Methods: This multi-centre study was performed for one year with the participation of 11 out of 16 tertiary allergy/clinical immunology clinics in Turkey. The study group consisted of the patients with DH reactions. Results of a questionnaire including drug reactions and management were recorded. Results: Among 54,863 patients, 1000 patients with DH were enrolled with a median of 2.1% of all admissions. In real life conditions, the majority of approaches were performed for finding safe alternatives (65.5%; 1102 out of 1683) with 11.7% positivity. Diagnostic procedures were positive in 27% (154/581) of the patients. The majority of the patients had higher VAS scores for anxiety. A total of 250 subjects (25%) reported that they delayed some medical procedures because of DH. Conclusion: Our results documented the frequency of admissions due to DH reactions to allergy/clinical immunology clinics for the first time. Although physicians mostly preferred to perform drug tests in order to find safe alternatives, considering the fact that DH was confirmed in 27% of the patients, use of diagnostic tests should be encouraged, if no contraindication exists in order to avoid mislabelling patients as DH. (C) 2013 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.